These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 3182416

  • 41. In-vitro activity of meropenem against clinical isolates in a multicentre study in Italy.
    Schito GC, Sanna A, Chezzi C, Ravizzola G, Leone F, Molinari G, Menozzi MG, Pirali F.
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():57-72. PubMed ID: 2681128
    [Abstract] [Full Text] [Related]

  • 42. In vitro activities of A-56619 (difloxacin) and A-56620, two aryl fluoroquinolones.
    Digranes A, Dibb WL.
    Chemotherapy; 1988 Sep; 34(4):298-307. PubMed ID: 3208547
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. In vitro activity of Bay y 3118, a new quinolone.
    Fass RJ.
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2348-57. PubMed ID: 8285618
    [Abstract] [Full Text] [Related]

  • 45. Comparative in vitro activity of lomefloxacin, a new difluoroquinolone.
    Clarke AM, Zemcov SJ.
    Eur J Clin Microbiol Infect Dis; 1989 Feb; 8(2):164-8. PubMed ID: 2498101
    [Abstract] [Full Text] [Related]

  • 46. Comparative in vitro activity of PD 127,391, a new fluorinated 4-quinolone derivative.
    Norrby SR, Jonsson M.
    Antimicrob Agents Chemother; 1988 Aug; 32(8):1278-81. PubMed ID: 3142352
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Temafloxacin: in vitro comparison with five other antibacterial agents.
    Digranes A, Hardardottir H, Bottolfsen KL.
    Chemotherapy; 1991 Aug; 37(2):98-105. PubMed ID: 2032475
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Newly documented antimicrobial activity of quinolones.
    Furet YX, Pechère JC.
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):249-54. PubMed ID: 1864284
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Lomefloxacin activity against 2,813 clinical isolates: a collaborative study at three medical centers in Brazil.
    Magalhaes M, Trabulsi LR, Montelli AC.
    Diagn Microbiol Infect Dis; 1989 Apr; 12(3 Suppl):35S-39S. PubMed ID: 2791496
    [Abstract] [Full Text] [Related]

  • 56. In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria.
    Liebetrau A, Rodloff AC, Behra-Miellet J, Dubreuil L.
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3667-71. PubMed ID: 14576144
    [Abstract] [Full Text] [Related]

  • 57. Comparative in-vitro activity of tigemonam, a new monobactam.
    Rylander M, Gezelius L, Norrby SR.
    J Antimicrob Chemother; 1988 Sep; 22(3):307-13. PubMed ID: 3182428
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Susceptibility of bacterial isolates from AIDS patients to six fluoroquinolones.
    Lewin CS, Naden M, Watt B, Amyes SG.
    J Pharm Pharmacol; 1990 Nov; 42(11):808-9. PubMed ID: 1982310
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.